May Measurement Month 2017: an analysis of blood pressure screening results from the United Arab Emirates-Northern Africa and Middle East.


Journal

European heart journal supplements : journal of the European Society of Cardiology
ISSN: 1520-765X
Titre abrégé: Eur Heart J Suppl
Pays: England
ID NLM: 100886647

Informations de publication

Date de publication:
Apr 2019
Historique:
accepted: 15 02 2019
entrez: 3 5 2019
pubmed: 3 5 2019
medline: 3 5 2019
Statut: ppublish

Résumé

Elevated blood pressure (BP) is a growing burden worldwide, leading to over 10 million deaths each year. May Measurement Month (MMM) is a global initiative aimed at raising awareness of high BP and to act as a temporary solution to the lack of screening programmes worldwide. United Arab Emirates has a young population, but cardiovascular disease (CVD) is the commonest cause of death (40%). Myocardial infarction and stroke occurs at least a decade earlier than in western countries. Previous screening in our young population showed that 85% of the population had at least one CVD risk factor and about 62% of them were unaware of it. An opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in May 2017. Blood pressure measurement, the definition of hypertension and statistical analysis followed the standard MMM protocol. Screening was held in 23 sites such as mosques, sports, and men's/ladies' clubs, airports, parks, shopping malls, work places as well as their residences, and in the public areas of hospitals or outpatient clinics. A total of 6193 individuals were screened during MMM17. The mean age was 39.2 ± 13.1 years. After multiple imputation, 1867 (30.2%) had hypertension. Of individuals not receiving anti-hypertensive medication, 813 (15.8%) were hypertensive. Of 1054 individuals receiving anti-hypertensive medication, 427 (40.6%) had uncontrolled BP. MMM17 was a useful screening model as it makes BP measurement easily accessible. Eight hundred and thirteen (16%) possibly new hypertensives were uncovered and 427(40.6%) of those on treatment for hypertension were found to be uncontrolled. These results suggest that opportunistic screening can identify significant numbers with raised BP.

Identifiants

pubmed: 31043897
doi: 10.1093/eurheartj/suz074
pii: suz074
pmc: PMC6479438
doi:

Types de publication

Journal Article

Langues

eng

Pagination

D118-D120

Références

Am J Public Health. 2012 May;102(5):909-14
pubmed: 21940918
BMC Cardiovasc Disord. 2015 May 07;15:30
pubmed: 25948543
Glob Heart. 2015 Dec;10(4):265-72
pubmed: 26271552
Heart Asia. 2010 Oct 05;2(1):118-21
pubmed: 27325958
Lancet. 2016 Aug 20;388(10046):761-75
pubmed: 27431356
J Hypertens. 2017 Jul;35(7):1457-1464
pubmed: 28486270
Lancet Glob Health. 2018 Jul;6(7):e736-e743
pubmed: 29778399

Auteurs

Afzalhussein Yusufali (A)

Hatta Hospital, Dubai Health Authority/Dubai Medical University, Dubai, UAE.
Dubai Medical University, Dubai, UAE.

Nooshin Bazargani (N)

Dubai Hospital, Dubai Health Authority, Dubai, UAE.

Amrish Agrawal (A)

Fujairah Hospital, Ministry of Health and Prevention, Fujairah, UAE.

Khalifa Muhammed (K)

Rashid Hospital, Dubai Health Authority, Dubai, UAE.

Hanan Obaid (H)

Primary Health Care, Dubai Health Authority, Dubai, UAE.

Ahmed Gabroun (A)

United Medical Center, Dubai, UAE.

Mouza Albadwawi (M)

Hatta Hospital, Dubai Health Authority/Dubai Medical University, Dubai, UAE.

Amer Albawab (A)

Hatta Hospital, Dubai Health Authority/Dubai Medical University, Dubai, UAE.

Anas Musa (A)

Rashid Hospital, Dubai Health Authority, Dubai, UAE.

Fatima Alraeesi (F)

Dubai Medical University, Dubai, UAE.

Zainab Vazir (Z)

Rashid Hospital, Dubai Health Authority, Dubai, UAE.

Rekha Varghese (R)

Hatta Hospital, Dubai Health Authority/Dubai Medical University, Dubai, UAE.

Rajakumari Ravi Kumar (R)

Hatta Hospital, Dubai Health Authority/Dubai Medical University, Dubai, UAE.

Elsa Kobeissi (E)

Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.

Thomas Beaney (T)

Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.

Neil R Poulter (NR)

Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.

Classifications MeSH